

Supplemental Information

Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in a twin study

Helena Lapatto, Minna Kuusela, Aino Heikkinen, Maheswary Muniandy, Birgitta W. van der Kolk, Swetha Gopalakrishnan, Martin Sandvik, Mark S. Schmidt, Sini Heinonen, Sina Saari, Noora Pöllänen, Juho Kuula, Antti Hakkarainen, Janne Tampio, Tuure Saarinen, Marja-Riitta Taskinen, Nina Lundbom, Per-Henrik Groop, Marja Tirola, Pekka Katajisto, Marko Lehtonen, Charles Brenner, Jaakko Kaprio, Satu Pekkala, Miina Ollikainen, Kirsi H. Pietiläinen and Eija Pirinen




Fig. S1. Flow chart illustrating the procedures for selection of study participants and data analyses, Related to Figure 1A. Presented as (n=number of twin pairs/number of individuals).




Fig. S2. Baseline NAD⁺ metabolism in the twins from the BMI-discordant pairs and the effect of placebo and NR treatments on NAD metabolome in the twins from the BMI-concordant pairs. Related to Figure 1. Number of analyzed study participants is presented as n=number of full twin pairs/number of individuals.

(A-F) Concentration of whole blood NAD metabolites at baseline in the twins from the BMI-discordant pairs (n=14 pairs/28 individuals).

(G) Expression of genes associated with NAD⁺ biosynthesis in muscle at baseline in the twins from the BMI-discordant pairs (n=11-15 pairs/22-30 individuals).

(H) Expression of genes associated with NAD⁺ biosynthesis in WAT at baseline in the twins from the BMI-discordant pairs (n=9-14 pairs/18-28 individuals).

(I-N) Concentration of whole blood NAD metabolites in placebo and NR treated BMI-concordant twin pairs (n=4 pairs/8 individuals). One cotwin of the twin pair was treated with NR (in black) and the other cotwin with placebo (in blue).

Pre and post values of an individual study subject are connected with a line. Fold change (FC) indicates either the mean of the heavier cotwin values divided with the leaner cotwin values (baseline graphs) or post NR values divided by pre values (pre versus post graphs). FC could not be calculated for NAAD as its concentration at baseline was zero. Arbitrary unit (au) indicates relative gene expression normalized to expression of housekeeping genes. Paired Wilcoxon signed-rank test was used as the statistical test. NAAD, nicotinic acid adenine dinucleotide; NMN, nicotinamide mononucleotide; Me4PY, N-methyl-4-pyridone-5-carboxamide; NADP, nicotinamide adenine dinucleotide phosphate; ADPR, ADP ribose.




Fig. S3. Expression of mitochondrial metabolism related genes in muscle and WAT and WAT mitochondrial DNA amount before and after NR treatment in the twins from the BMI-discordant pairs. Related to Figure 2. Number of analyzed study participants is presented as n=number of full twin pairs/number of individuals.

(A) Gene expression of OXPHOS complex (I-V) subunits in muscle pre versus post NR (n= 10-13 pairs/21-26 individuals).
 (B) Expression of mitochondrial quality control and fatty acid oxidation genes in muscle pre versus post NR (n= 11-13 pairs/23-26 individuals).
 (C) Mitochondrial DNA amount in WAT pre versus post NR (n=14-15 pairs/28-31 individuals).
 (D) Gene expression levels of the regulators of mitochondrial biogenesis in WAT pre versus post NR (n=10-13 pairs/21-27 individuals)
 (E) Gene expression levels of OXPHOS complex (I-V) subunits in WAT pre vs post NR (n=9-13 pairs/19-26 individuals).
 (F) Expression levels of mitochondrial quality control genes in WAT pre vs post NR (n= 11 pairs/22-23 individuals).

Pre and post values of an individual study subject are connected with a line and leaner twins are in black, heavier in red. Fold change (FC) indicates either mean of post NR values divided by pre values. Paired Wilcoxon signed-rank test was used as the statistical test. Arbitrary unit (au) indicates relative gene expression normalized to expression of housekeeping genes or mitochondrial amount expressed relative to nuclear genome amount. mtDNA, mitochondrial amount.

Table S1. Baseline characteristics of the twins from the BMI-discordant and -concordant pairs.

Variable (unit)	Discordant All (n=32 individuals)	Leaner (n=16 individuals)	Heavier (n=16 individuals)	P Value	Concordant All (n=8 individuals)	Concordant Placebo (n=4 individuals)	Concordant Treated (n=4 individuals)	P Value
Age (years)	39.7 (33.1 - 41.1)	39.7 (33.1 - 41.1)	39.7 (33.1 - 41.1)	-	40.5 (37.8 - 41.3)	40.5 (37.8 - 41.3)	40.5 (37.8 - 41.3)	-
Sex (female, %)	44	44	44	-	50	50	50	-
Height (cm)	173.4 ± 10.9	173.5 ± 11.5	173.3 ± 10.7	0.477	167.4 ± 10.1	167.4 ± 11.1	167.4 ± 10.8	0.875
BMI (kg/m ²)	30.1 ± 5.7	27.4 ± 4.2	32.8 ± 5.8	<0.001	31.7 ± 6.4	31.5 ± 6.8	32.0 ± 6.9	0.269
Weight (kg)	90.7 ± 19.8	82.7 ± 17.2	98.6 ± 19.5	<0.001	88.1 ± 13.5	87.2 ± 12.2	89.1 ± 16.6	0.625
Waist-hip ratio	0.96 ± 0.09	0.9 ± 0.1	1.0 ± 0.1	<0.001	0.94 ± 0.04	0.9 ± 0.0	1.0 ± 0.0	0.250
Body fat (%)	37.1 ± 8.2	34.0 ± 7.8	40.2 ± 7.6	<0.001	33.4 ± 12.8	34.1 ± 13.8	33.1 ± 14.8	1.000
Visceral adipose tissue (cm ³)	2155 ± 878	1754 ± 786	2556 ± 799	0.001	2117 ± 693	2017 ± 497	2217 ± 921	0.875
Subcutaneous adipose tissue (cm ³)	6461 ± 3001	5325 ± 2442	7597 ± 3155	<0.001	7146 ± 4461	7297 ± 4799	6996 ± 4831	0.250
Adipocyte cell number (per billion)	301 (194 - 505)	288 (173 - 383)	357 (203 - 581)	0.010	191 (173 - 267)	233 (197 - 308)	168 (147 - 204)	0.125
Adipocyte cell diameter (µM)	93 ± 11	88 ± 10	97 ± 8.9	0.002	93 ± 12	89 ± 11	96 ± 12	0.250
Adipocyte cell volume (pL)	598 ± 201	508 ± 213	689 ± 145	0.007	559 ± 186	500 ± 154	617 ± 219	0.250
Adipocyte cell weight (ng)	583 (429 - 641)	435 (306 - 572)	627 (583 - 740)	0.007	452 (365 - 674)	407 (364 - 500)	584 (427 - 722)	0.250
PPAR γ , adipose tissue (au)	0.95 ± 0.30	1.00 ± 0.34	0.91 ± 0.25	0.569	ND	ND	ND	ND
Liver fat (%)	1.7 (0.8 - 4.6)	1.2 (0.5 - 2.0)	2.3 (1.4 - 9.2)	0.010	3.4 (1.2 - 8.7)	5.2 (0.88 - 9.9)	3.4 (2.0 - 5.4)	0.625
Lean tissue mass (kg)	54.0 ± 10.2	52.0 ± 9.6	56.1 ± 10.5	<0.001	57.5 ± 4.9	56.2 ± 5.5	58.8 ± 4.9	0.250
Total bone mass (kg)	2.9 ± 0.6	2.8 ± 0.6	2.9 ± 0.6	<0.001	3.2 ± 0.5	3.2 ± 0.6	3.3 ± 0.5	0.500
Basal metabolic rate (kcal/day)	1874 ± 382	1780.8 ± 370.4	1967.7 ± 380.9	<0.001	1797.9 ± 262.1	1782.3 ± 265.8	1813.5 ± 298.3	0.625
Caloric intake (kcal/day)	2297 ± 441	2244.3 ± 434.4	2349.9 ± 455.7	0.463	2003.1 ± 655.0	1872.0 ± 419.2	2134.2 ± 882.8	1.000

Protein intake (g)	96.2 (81.6 - 115)	95.6 (84.5 - 115.3)	96.3 (79.2 - 116.4)	0.900	81.8 (65.3 - 103.5)	81.5 (6.2 - 100.2)	84.0 (65.7 - 110.1)	0.625
Fat intake (g)	103.6 ± 28.5	97.7 ± 26.0	109.6 ± 30.4	0.562	78.4 ± 29.7	69.8 ± 17.5	87.1 ± 39.5	0.875
Carbohydrate intake (g)	211.5 ± 51.1	216.0 ± 50.0	207.0 ± 53.4	0.744	212.4 ± 68.2	234.9 ± 55.1	221.3 ± 93.2	0.875
Niacin equivalent (mg/day)	44.5 (36.1 - 49.9)	45.4 (36.7 - 49.3)	43.9 (33.5 - 52.9)	0.706	33.0 (31.0 - 40.7)	32.4 (30.6 - 36.5)	35.8 (31.9 - 41.6)	0.875
Physical activity (Total Baecke)	7.8 ± 1.5	8.0 ± 1.7	7.7 ± 1.4	0.802	8.4 ± 1.4	8.1 ± 0.7	8.7 ± 1.9	0.750
Alcohol consumption (doses/week)	1.0 (0.0 - 2.0)	0.9 (0 - 3.8)	5.0 (1.8 - 9.3)	0.009	1.0 (0.0 - 2.9)	1.0 (0.5 - 1.4)	2.0 (0.0 - 4.6)	0.371
Current smoker (number)	7	4	3	-	3	2	1	-
HbA1c (mmol/mol)	34 (32 - 36)	34 (32 - 35)	35 (34 - 36)	0.037	36 (33 - 37)	35 (33 - 36)	37 (35 - 38)	1.000
Fasting glucose (mmol/l)	5.6 (5.4 - 5.8)	5.6 (5.3 - 5.7)	5.7 (5.4 - 5.8)	0.157	5.8 (5.1 - 5.8)	5.4 (5.0 - 5.8)	5.8 (5.6 - 5.8)	0.375
Fasting insulin (mIU/l)	6.0 (4.5 - 9.8)	4.7 (3.8 - 6.7)	7.9 (5.3 - 12.5)	0.018	8.0 (3.9 - 12.9)	7.7 (3.9 - 11.5)	9.7 (4.1 - 14.9)	0.375
Fasting C-peptide (nmol/l)	0.51 (0.39 - 0.65)	0.47 (0.39 - 0.60)	0.56 (0.43 - 0.83)	0.018	0.69 (0.44 - 1.1)	0.69 (0.41 - 0.98)	0.80 (0.44 - 1.2)	0.125
HOMA index	1.5 (1.0 - 2.1)	1.1 (0.94 - 1.6)	2.0 (1.3 - 3.2)	0.022	1.9 (0.96 - 3.4)	1.8 (0.96 - 2.7)	2.5 (1.0 - 3.8)	0.250
Matsuda index	5.7 ± 2.5	6.8 ± 2.4	4.7 ± 2.1	<0.001	8.2 ± 6.2	8.8 ± 6.9	7.5 ± 6.5	0.125
Glucose AUC during OGTT	15.7 ± 2.5	15.2 ± 2.5	16.2 ± 2.4	0.042	15.8 ± 3.6	14.8 ± 4.1	16.8 ± 3.3	0.125
Insulin AUC during OGTT	90 (72 - 135)	85.3 (67.7 - 116.9)	96.6 (78.4 - 175.2)	0.006	95.5 (30.9 - 188.0)	90.0 (30.3 - 161.3)	115.2 (39.2 - 188.0)	0.625
Adiponectin (µg/ml)	3.2 (2.1 - 4.3)	3.2 (2.7 - 3.8)	3.1 (1.6 - 5.2)	0.454	3.4 (2.2 - 8.5)	3.4 (2.8 - 6.8)	5.2 (3.6 - 6.9)	0.500
Cholesterol (total, mmol/l)	4.7 ± 0.8	4.7 ± 0.7	4.7 ± 0.9	0.660	4.8 ± 0.6	4.7 ± 0.5	4.8 ± 0.8	0.875
HDL (mmol/l)	1.3 (1.2 - 1.6)	1.4 (1.2 - 1.5)	1.3 (1.1 - 1.7)	0.224	1.3 (1.2 - 1.5)	1.3 (1.2 - 1.4)	1.4 (1.2 - 1.6)	0.625
LDL (mmol/l)	3.0 ± 0.77	3.0 ± 0.71	3.1 ± 0.83	0.196	3.2 ± 0.41	3.1 ± 0.41	3.3 ± 0.45	0.586
Triglycerides (mmol/l)	0.95 (0.71 - 1.2)	0.81 (0.61 - 1.0)	1.0 (0.73 - 1.3)	0.118	1.0 (0.70 - 1.1)	1.0 (0.88 - 1.0)	0.92 (0.70 - 1.2)	0.625
FFA (µmol/l)	444 (376 - 551)	415 (362 - 500)	510 (428 - 700)	0.542	398 (332 - 527)	427.7 (325.4 - 531.4)	394.1 (332.1 - 481.9)	0.625

Systolic BP (mmHg)	133 ± 22	131 ± 24	135 ± 22	0.141	120 ± 12	114 ± 12	126 ± 7.8	0.098
Diastolic BP (mmHg)	83 ± 12	83 ± 12	84 ± 11	0.706	77 ± 8	77 ± 7.7	80 ± 5.9	0.197
Pulse (per min)	66.9 ± 10.7	64.5 ± 9.2	69.3 ± 11.8	0.084	61.9 ± 6.4	63.0 ± 8.0	60.8 ± 5.1	0.461
Hs-CRP (mg/l)	1.9 (0.67 - 3.9)	1.7 (0.61 - 3.0)	2.3 (0.73 - 5.8))	0.117	1.3 (0.83 - 5.4)	1.6 (1.3 - 10.7)	0.99 (0.55 - 3.3)	0.250
Total homocysteine (µmol/l)	11.0 (9.30 - 12.0)	10.0 (9.55 - 12.0)	11.0 (9.28 - 12.8)	0.500	13.0 (11.5 - 13.8)	13.0 (12.2 - 13.8)	12.5 (11.5 - 15.0)	1.000
ALT (U/l)	22.0 (17.8 - 42.8)	20.0 (16.5 - 33.5)	33.0 (19.5 - 49.0)	0.012	22.5 (19.8 - 32.0)	23.5 (18.3 - 38.8)	22.5 (21.5 - 28.3)	0.581
AST (U/l)	24.0 (21.8 - 31.0)	24.0 (19.8 - 29.2)	24.0 (22.8 - 31.0)	0.139	26.5 (24.0 - 29.5)	26.5 (24.8 - 30.0)	26.5 (24.0 - 29.5)	0.586
Creatinine (µmol/l)	73.7 ± 12.9	73.2 ± 13.6	74.3 ± 12.7	0.569	76.6 ± 12.0	74.0 ± 13.2	79.3 ± 12.1	0.125
Haemoglobin (g/l)	142 ± 9	142 ± 8	143 ± 9	0.659	136 ± 11	137 ± 10	136 ± 13	0.625
Haematocrit (%)	42.0 ± 2.2	41.9 ± 2.1	42.1 ± 2.4	0.680	40.6 ± 3.2	40.8 ± 2.9	40.5 ± 3.9	0.850
Erythrocytes (x10 ¹² /l)	4.8 ± 0.3	4.8 ± 0.37	4.8 ± 0.31	0.103	4.5 ± 0.4	4.5 ± 0.4	4.6 ± 0.5	0.875
MCV (fl)	87.9 ± 3.5	88.4 ± 4.2	87.4 ± 2.6	0.162	89.0 ± 3.3	90.3 ± 2.1	87.8 ± 4.2	0.098
MCH (pg)	29.8 ± 1.3	29.9 ± 1.5	29.6 ± 1.2	0.182	30.1 ± 1.4	30.5 ± 1.0	29.8 ± 1.7	0.371
MCHC (g/l)	338 (334 - 342)	338 (334 - 342)	337 (335 - 342)	0.609	338 (334.5 - 335.3)	338.0 (335.5 - 339.8)	338.5 (334.5 - 342.5)	0.345
Leukocytes (x10 ⁹ /l)	6.4 ± 1.5	6.5 ± 1.8	6.3 ± 1.2	0.816	6.7 ± 2.3	7.3 ± 3.0	6.2 ± 1.7	0.423
Thrombocytes (x10 ⁹ /l)	243 ± 55	244 ± 60	241 ± 52	0.860	247 ± 42	234 ± 29	260 ± 53	0.125
fP-Fe (µmol/l)	19.0 ± 6.9	19.8 ± 7.6	18.1 ± 6.3	0.469	20.0 ± 7.3	20.0 ± 6.4	20.0 ± 9.1	0.875

Data are shown as mean ± standard deviation or median (interquartile range). P values were obtained using paired Wilcoxon rank-sum test to examine the differences on anthropometric and clinical parameters between the cotwins at baseline in the twins from the BMI-discordant (n=16 twin pairs/32 individuals) and concordant (n=4 twin pairs/8 individuals) pairs. *PPAR*γ, peroxisome proliferator-activated receptor γ; Au, arbitrary unit; ND, not determined; HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment; AUC, area under curve; OGTT, oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acids; BP, blood pressure; Hs-CRP, high sensitive C-reactive protein; ALT, alanine aminotransferase; AST, aspartate transaminase; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; fP, fasting plasma and Fe, iron.

Table S2. The delta response (the change from baseline to 5 months) to NR in the twins from the BMI-discordant pairs.

Variable (unit)	Leaner Δ (n=16 individuals)	Heavier Δ (n=16 individuals)	P Value
<i>NAD metabolites</i>			
NAD ⁺ , whole blood (μ M)	30.1 \pm 20.0	33.4 \pm 12.1	0.519
NAAD, whole blood (μ M)	0.15 (0.08 - 0.34)	0.26 (0.11 - 0.31)	0.533
NMN, whole blood (μ M)	0.12 \pm 0.15	0.23 \pm 0.08	0.139
NAR, whole blood (μ M)	0.0 (0.0 - 0.0)	0.0 (0.0 - 0.0)	1.000
Me4py, whole blood (μ M)	1.6 \pm 0.59	1.9 \pm 0.46	0.014
NADP, whole blood (μ M)	-0.82 (-1.7 - -0.69)	-0.15 (-0.88 - 0.60)	0.175
ADPR, whole blood (μ M)	-0.85 \pm 3.1	0.42 \pm 2.8	0.557
<i>Expression of NAD⁺ biosynthesis genes</i>			
NRK1, muscle (au)	0.08 \pm 0.14	0.04 \pm 0.13	0.424
NAMPT, muscle (au)	0.13 (-0.04 - 0.29)	0.19 (0.09 - 0.18)	0.742
NMNAT3, muscle (au)	-0.24 \pm 0.27	-0.06 \pm 0.26	0.129
NAPRT, muscle (au)	-0.10 \pm 0.20	-0.10 \pm 0.21	1.000
NRK1, adipose tissue (au)	0.01 \pm 0.28	0.19 \pm 0.23	0.068
NAMPT, adipose tissue (au)	0.06 (-0.08 - 0.23)	-0.04 (-0.13 - 0.20)	0.922
NMNAT3, adipose tissue (au)	0.01 (-0.25 - 0.24)	0.09 (0.04 - 0.23)	0.110
NAPRT, adipose tissue (au)	-0.05 (-0.24 - 0.12)	-0.15 (-0.50 - -0.05)	0.938
<i>Anthropometric and body composition</i>			
BMI (kg/m ²)	0.89 \pm 1.5	1.0 \pm 1.2	0.224
Weight (kg)	2.7 \pm 4.3	2.6 \pm 3.4	0.339
Body fat (%)	1.5 \pm 2.6	0.62 \pm 2.2	0.404
Visceral adipose tissue (cm ³)	250 \pm 307	101 \pm 560	0.610
Subcutaneous adipose tissue (cm ³)	683 \pm 1240	-46 \pm 1295	1.000
Adipose tissue (cm ³)	933 \pm 1476	55 \pm 1760	1.000
Adipocyte cell number (per billion)	-123 (-150 - -4.0)	-6.2 (-337 - 95)	0.599
Adipocyte cell diameter (μ M)	4.5 \pm 16	1.0 \pm 17	0.454
Adipocyte cell volume (pL)	111 \pm 356	110 \pm 17	0.639
Adipocyte cell weight (ng)	-6.3 (-113 - 186)	38 (-159 - 365)	0.639
PPAR γ , adipose tissue (au)	0.13 \pm 0.26	0.15 \pm 0.22	0.765
Waist-hip ratio	0.02 \pm 0.05	0.00 \pm 0.03	0.211
Liver fat (%)	0.05 (-0.25 - 0.55)	-0.10 (-0.70 - 1.10)	0.635
Lean tissue mass (g)	158 \pm 1234	747 \pm 1322	0.193
Total bone mass (g)	10.5 \pm 32.2	6.6 \pm 17.4	0.940
Basal metabolic rate (kcal/day)	30.8 \pm 54.0	47.0 \pm 44.4	0.313
Caloric intake (kcal/day)	20 \pm 627	-135 \pm 687	0.562
Niacin equivalent (mg/day)	-4.0 (-12.5 - 2.1)	0.47 (-14.7 - 11.2)	0.528
Physical activity (Total Baecke)	0.0 \pm 1.5	-0.3 \pm 0.6	0.401
Alcohol intake (doses/week)	0.49 (0.0 - 0.94)	-0.19 (-0.50 - 0.13)	0.074
<i>Glucose homeostasis</i>			
HbA1c (mmol/mol)	1.0 (0.0 - 1.0)	0.0 (-2.0 - 1.5)	0.037
Fasting glucose (mmol/l)	0.10 (-0.10 - 0.20)	0.20 (-0.10 - 0.33)	0.089

Fasting insulin (mIU/l)	1.2 (-0.1 - 4.1)	1.5 (-1.2 - 3.6)	0.670
Fasting C-peptide (nmol/l)	0.05 (0.01 - 0.15)	0.11 (-0.0 - 0.18)	0.599
HOMA index	0.35 (-0.11 - 1.0)	0.37 (-0.22 - 0.98)	0.804
Matsuda index	-1.4 ± 2.1	-1.0 ± 1.8	0.305
Glucose AUC during OGTT	0.3 ± 2.2	0.6 ± 1.4	0.635
Insulin AUC during OGTT	14.8 (-8.8 - 30.7)	11.0 (-1.6 - 64.8)	0.635
Adiponectin (ng/ml)	17 (-111 - 516)	-105 (-796 - 364)	0.151
<i>Cardiovascular health</i>			
Cholesterol (total, mmol/l)	0.03 ± 0.33	0.07 ± 0.32	0.889
HDL (mmol/l)	-0.08 (-0.17 - 0.03)	-0.05 (-0.18 - 0.08)	0.231
LDL (mmol/l)	0.03 ± 0.35	-0.08 ± 0.59	0.551
Triglycerides (mmol/l)	0.13 (-0.11 - 0.26)	0.15 (-0.08 - 0.27)	0.231
FFA (μmol/l)	-9.48 (-89.3 - 47.7)	36.5 (-154 - 66.5)	0.542
Systolic BP (mmHg)	-4.0 ± 17.5	-1.7 ± 17.5	0.615
Diastolic BP (mmHg)	-0.5 ± 9.5	1.1 ± 13.9	0.624
Pulse (per min)	2.1 ± 9.1	0.14 ± 12.9	0.575
Hs-CRP (mg/l)	0.13 (-0.39 - 0.65)	-0.07 (-0.43 - 0.71)	0.391
Total homocysteine (μmol/l)	2.0 (0.15 - 2.5)	0.90 (-0.93 - 1.2)	0.024
<i>Mitochondrial parameters</i>			
Mitochondrial number, muscle (number/muscle fiber area/10 μm ²)	12.6 ± 23.0	12.0 ± 29.9	1.000
Mitochondrial area, muscle (relative area %)	0.67 (0.01 - 1.12)	0.91 (-0.33 - 2.2)	1.000
Mitochondrial perimeter (μm)	-0.02 ± 0.28	0.04 ± 0.35	0.966
Mitochondrial diameter (μm)	0.01 (-0.02 - 0.02)	-0.02 (-0.02 - 0.02)	0.413
Mitochondrial form factor	-0.09 (-0.17 - 0.25)	0.07 (-0.06 - 0.27)	0.365
Mitochondrial aspect ratio	-0.05 (-0.25 - 0.26)	0.09 (-0.08 - 0.24)	0.240
16S, muscle (au)	0.27 (0.25 - 0.53)	0.30 (0.01 - 0.68)	0.846
CYTB, muscle (au)	0.31 (0.16 - 0.37)	0.18 (0.11 - 0.47)	0.622
DLOOP, muscle (au)	0.29 ± 0.16	0.31 ± 0.24	0.922
16S, adipose tissue (au)	-0.09 ± 0.42	-0.19 ± 0.40	0.542
CYTB, adipose tissue (au)	-0.06 (-0.52 - 0.06)	-0.04 (-0.34 - 0.08)	0.635
DLOOP, adipose tissue (au)	-0.11 ± 0.41	-0.11 ± 0.34	0.934
ERRα, muscle (au)	0.15 ± 0.23	0.15 ± 0.19	0.413
NRF1, muscle (au)	-0.08 ± 0.25	-0.16 ± 0.32	0.547
PGC1α, muscle (au)	-0.07 ± 0.35	-0.04 ± 0.38	0.791
TFAM, muscle (au)	0.16 ± 0.34	0.28 ± 0.36	0.244
MFN2, muscle (au)	0.14 ± 0.15	0.06 ± 0.21	0.520
NDUFB8, muscle (au)	-0.09 ± 0.25	-0.19 ± 0.27	0.770
MT-ND5, muscle (au)	-0.10 (-0.59 - 0.20)	-0.17 (-0.44 - 0.01)	0.893
SDHB, muscle (au)	-0.04 ± 0.24	0.12 ± 0.55	0.734
UQCRC2, muscle (au)	0.01 ± 0.19	0.02 ± 0.23	0.685
COX4, muscle (au)	-0.07 (-0.18 - 0.16)	0.05 (-0.14 - 0.26)	0.938
MT-CO1, muscle (au)	-0.06 ± 0.31	-0.02 ± 0.42	0.820
ATP5A, muscle (au)	0.10 ± 0.22	0.14 ± 0.16	0.910
CLPP, muscle (au)	-0.01 ± 0.17	0.04 ± 0.19	0.557

<i>HSPD1</i> , muscle (au)	-0.04 ± 0.26	0.00 ± 0.25	0.733
<i>CPT1β</i> , muscle (au)	-0.15 ± 0.63	-0.03 ± 0.73	0.765
<i>ERRα</i> , adipose tissue (au)	-0.07 ± 0.46	-0.02 ± 0.27	0.339
<i>NRF1</i> , adipose tissue (au)	0.08 (-0.03 - 0.16)	0.11 (-0.09 - 0.21)	0.787
<i>TFAM</i> , adipose tissue (au)	-0.02 ± 0.39	-0.05 ± 0.26	1.000
<i>MFN2</i> , adipose tissue (au)	-0.07 ± 0.21	-0.05 ± 0.25	0.898
<i>NDUFB8</i> , adipose tissue (au)	-0.30 (-0.52 - -0.07)	-0.36 (-0.42 - -0.11)	0.588
<i>MT-ND5</i> , adipose tissue (au)	-0.19 (-0.38 - 0.02)	-0.17 (-0.43 - 0.01)	0.622
<i>SDHB</i> , adipose tissue (au)	-0.05 (-0.25 - 0.09)	-0.07 (-0.13 - 0.11)	0.742
<i>UQCRC2</i> , adipose tissue (au)	0.30 ± 0.38	0.16 ± 0.26	0.426
<i>COX4</i> , adipose tissue (au)	0.04 (-0.39 - 0.30)	-0.01 (-0.15 - 0.11)	1.000
<i>MT-CO1</i> , adipose tissue (au)	0.02 (-0.14 - 0.11)	-0.13 (-0.30 - -0.17)	0.734
<i>ATP5A</i> , adipose tissue (au)	-0.04 ± 0.32	0.06 ± 0.23	0.365
<i>CLPP</i> , adipose tissue (au)	-0.05 (-0.28 - 0.08)	-0.02 (-0.13 - 0.08)	0.359
<i>HSPD1</i> , adipose tissue (au)	0.03 (-0.05 - 0.14)	-0.01 (-0.07 - 0.17)	0.320
<i>Satellite cells</i>			
<i>PAX7</i> , muscle (au)	-0.31 ± 0.30	-0.26 ± 0.45	0.688
<i>PAX7</i> positive cells (<i>PAX7</i> + cells/muscle fiber area)	-6.4 ± 3.6	-3.9 ± 2.6	0.578
<i>PAX7/MYOG</i> (ratio)	-0.63 ± 0.75	-1.1 ± 0.22	0.500

Data are shown as mean ± SD (normally distributed variables), median (interquartile range, for skewed variables). P values were obtained using paired Wilcoxon rank-sum test to examine the differences on delta change (the change from baseline to 5 months) for anthropometric and clinical parameters between the leaner and heavier cotwins from the BMI-discordant pairs (n=16 twin pairs/32 individuals). NAAD, nicotinic acid adenine dinucleotide; NMN, nicotinamide mononucleotide; NAR, nicotinic acid riboside; Me4Py, N-methyl-4-pyridone-5-carboxamide; NADP, nicotinamide adenine dinucleotide phosphate; ADPR, ADP ribose; Au, arbitrary unit; *NRK1*, nicotinamide riboside kinase 1; *NAMPT*, nicotinamide phosphoribosyltransferase; *NMNAT3*, nicotinamide-nucleotide adenylyltransferase 3; *NAPRT*, nicotinic acid phosphoribosyltransferase; HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment; AUC, area under curve; OGTT, oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acids; BP, blood pressure; Hs-CRP, high sensitive C-reactive protein; 16S, 16 rRNA; CYTB, cytochrome b; DLOOP, D-loop region; *ERRα*, estrogen-related receptor α ; *NRF1*, nuclear respiratory factor 1; *PGC1α*, peroxisome proliferator-activated receptor gamma coactivator 1 α ; *TFAM*, transcription factor A; *MFN2*, mitofusin 2; *NDUFB8*, NADH:ubiquinone oxidoreductase subunit B8; *MT-ND5*, mitochondrially encoded NADH dehydrogenase 5; *SDHB*, succinate dehydrogenase complex iron sulfur subunit B; *UQCRC2*, ubiquinol-cytochrome c reductase core protein 2; *MT-CO1*, mitochondrially encoded cytochrome c oxidase 1; *ATP5A*, ATP synthase α ; *CLPP*, caseinolytic mitochondrial matrix peptidase proteolytic subunit; *HSPD1*, heat shock protein family D (Hsp60) member 1; *CPT1β*, carnitine palmitoyltransferase 1B; *PAX7*, paired box 7 and *MYOG*, myogenin.

Table S3. Glucose homeostasis in the twins from the BMI-discordant pairs upon NR supplementation.

Variable (unit)	All		P Value	Leaner		P Value	Heavier		P Value
	Pre (n=32 individuals)	Post (n=32 individuals)		Pre (n=16 individuals)	Post (n=16 individuals)		Pre (n=16 individuals)	Post (n=16 individuals)	
HbA1c (mmol/mol)	34 (32 - 36)	35 (33 - 36)	0.353	34 (32 - 35)	35 (33 - 36)	0.032	35 (34 - 36)	35 (32 - 37)	0.693
Fasting glucose (mmol/l)	5.6 (5.4 - 5.8)	5.7 (5.5 - 5.9)	0.027	5.6 (5.3 - 5.7)	5.7 (5.3 - 5.8)	0.483	5.7 (5.4 - 5.8)	5.8 (5.6 - 5.9)	0.018
Fasting insulin (mIU/l)	6.0 (4.5 - 9.8)	7.7 (6.2 - 13.4)	0.023	4.7 (3.8 - 6.7)	7.0 (5.9 - 9.0)	0.069	7.9 (5.3 - 12.5)	12.1 (7.1 - 14.6)	0.169
Fasting C-peptide (nmol/l)	0.51 (0.39 - 0.65)	0.63 (0.50 - 0.77)	0.002	0.47 (0.39 - 0.60)	0.55 (0.48 - 0.65)	0.022	0.56 (0.43 - 0.83)	0.74 (0.59 - 0.84)	0.036
HOMA index	1.5 (1.0 - 2.1)	2.0 (1.5 - 3.3)	0.016	1.1 (0.9 - 1.6)	1.7 (1.4 - 2.4)	0.073	2.0 (1.3 - 3.2)	3.0 (1.7 - 3.8)	0.135
Matsuda index	5.7 ± 2.5	4.4 ± 1.9	<0.001	6.8 ± 2.4	5.3 ± 2.0	0.068	4.7 ± 2.1	3.6 ± 1.4	0.042
Glucose AUC during OGTT	15.7 ± 2.5	16.1 ± 2.7	<0.001	15.2 ± 2.5	15.4 ± 2.6	0.286	16.2 ± 2.4	16.9 ± 2.8	0.208
Insulin AUC during OGTT	90 (72 - 135)	116 (88 - 160)	<0.001	85 (68 - 117)	112 (86 - 127)	0.217	97 (78 - 175)	154 (91 - 204)	0.173
Adiponectin (µg/ml)	3.2 (2.1 - 4.3)	3.2 (2.0 - 4.1)	0.946	3.2 (2.7 - 3.8)	3.3 (2.7 - 3.9)	0.495	3.1 (1.6 - 5.2)	2.8 (1.7 - 4.4)	0.277

Data are shown as mean ± SD (normally distributed variables), median (interquartile range, for skewed variables). P values were obtained using paired Wilcoxon rank-sum test to examine the effects of NR supplementation on anthropometric and clinical parameters before and after NR intervention in the twins from the BMI-discordant pairs (n=16 twin pairs/32 individuals). HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment; AUC, area under curve and OGTT, oral glucose tolerance test.

Table S4. The effect of NR on cardiovascular parameters in the twins from BMI-discordant pairs.

Variable (unit)	All		P Value	Leaner		P Value	Heavier		P Value
	Pre (n=32 individuals)	Post (n=32 individuals)		Pre (n=16 individuals)	Post (n=16 individuals)		Pre (n=16 individuals)	Post (n=16 individuals)	
Cholesterol (total, mmol/l)	4.7 ± 0.8	4.7 ± 0.8	0.346	4.7 ± 0.7	4.7 ± 0.7	0.568	4.7 ± 0.9	4.8 ± 1.0	0.470
HDL (mmol/l)	1.3 (1.2 - 1.6)	1.2 (1.0 - 1.6)	0.049	1.4 (1.2 - 1.5)	1.3 (1.1 - 1.7)	0.093	1.3 (1.1 - 1.7)	1.2 (1.0 - 1.6)	0.289
LDL (mmol/l)	3.0 ± 0.8	3.0 ± 0.5	0.723	3.0 ± 0.7	3.0 ± 0.5	0.752	3.1 ± 0.8	3.0 ± 0.5	0.887
Triglycerides (mmol/l)	1.0 (0.7 - 1.2)	0.9 (0.8 - 1.3)	0.046	0.81 (0.6 - 1.0)	0.9 (0.7 - 1.1)	0.313	1.0 (0.7 - 1.3)	1.1 (0.8 - 1.4)	0.088
FFA (µmol/l)	444 (376 – 551)	431 (368 – 546)	0.229	415 (362 - 500)	392 (322 – 432)	0.561	510 (428 - 700)	483 (420 – 562)	0.252
Systolic BP (mmHg)	133 ± 22	128 ± 19	0.531	131 ± 24	124 ± 19	0.683	135 ± 22	131 ± 19	0.753
Diastolic BP (mmHg)	83 ± 12	83 ± 11	0.875	83 ± 12	81 ± 11	0.889	84 ± 11	84 ± 12	1.000
Pulse (per min)	67 ± 11	67 ± 9	0.629	65 ± 9	66 ± 9	0.753	69 ± 12	69 ± 9	0.806
Hs-CRP (mg/l)	1.9 (0.7 - 3.9)	1.6 (0.6 - 4.0)	0.655	1.7 (0.6 - 3.0)	1.1 (0.5 - 2.9)	0.561	2.3 (0.7 - 5.8)	2.5 (0.9 - 4.7)	0.978
Total homocysteine (µmol/l)	11.0 (9.30 -12.0)	12.0 (10.0 - 14.0)	0.005	10.0 (9.55 -12.0)	12.0 (10.5 - 14.0)	0.003	11.0 (9.28 -12.8)	11.5 (10.3 - 14.0)	0.551

Data are shown as mean ± SD (normally distributed variables), median (interquartile range, for skewed variables). P values were obtained using paired Wilcoxon rank-sum test to examine the effect of NR supplementation on anthropometric and clinical parameters in the twins from the BMI-discordant pairs (n=16 twin pairs/32 individuals). HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acids; BP, blood pressure and Hs-CRP, high sensitive C-reactive protein.

Table S10. The effect of 5-month placebo and NR treatment in the twins from the BMI-concordant pairs.

Variable (unit)	Placebo Pre (n=4 individuals)	Placebo Post (n=4 individuals)	P Value	Treated Pre (n=4 individuals)	Treated Post (n=4 individuals)	P Value
BMI (kg/m ²)	31.5 ± 6.8	32.6 ± 7.3	0.125	32.0 ± 6.9	32.1 ± 6.7	0.875
Weight (kg)	87.2 ± 12.2	90.2 ± 13.2	0.125	89.1 ± 16.6	89.8 ± 15.2	0.581
Waist-hip ratio	0.9 ± 0.0	1.0 ± 0.0	0.250	0.9 ± 0.0	1.0 ± 0.1	0.250
Body fat (%)	34.1 ± 13.8	38.0 ± 12.3	0.250	33.2 ± 14.8	35.8 ± 13.3	0.750
Visceral adipose tissue (cm ³)	2017 ± 497	2275 ± 521	0.125	2217 ± 921	2171 ± 861	0.625
Subcutaneous adipose tissue (cm ³)	7297 ± 4799	7568 ± 4950	0.125	6996 ± 4831	6833 ± 4751	0.375
Adipocyte cell number (per billion)	233 (197 - 308)	289 (235 - 325)	1.000	168 (147 - 204)	315 (246 - 396)	0.125
Adipocyte cell diameter (µM)	89 ± 11	99 ± 8.6	0.375	96 ± 12	90 ± 5.6	0.125
Adipocyte cell volume (pL)	500 ± 154	734 ± 161	0.250	617 ± 219	573 ± 123	0.625
Adipocyte cell weight (ng)	407 (364 - 500)	702 (589 - 785)	0.250	584 (427 - 722)	559 (495 - 587)	0.625
Liver fat (%)	5.2 (0.87 - 9.9)	6.5 (1.5 - 12.0)	0.181	3.4 (2.0 - 5.4)	3.1 (1.9 - 4.8)	0.125
Lean tissue mass (kg)	56.2 ± 5.5	53.0 ± 8.8	0.750	58.8 ± 4.9	54.3 ± 9.7	1.000
Total bone mass (kg)	3.2 ± 0.6	3.0 ± 0.7	0.500	3.3 ± 0.5	3.0 ± 0.7	0.250
Basal metabolic rate (kcal/day)	1782 ± 266	1813 ± 260	0.250	1814 ± 298	1842 ± 262	0.125
Caloric intake (kcal/day)	1872 ± 419	1423 ± 730	0.250	2134 ± 883	1831 ± 1120	0.250
Protein intake (g)	81.5 (63.2 - 100.2)	89.5 (61.6 - 91.8)	1.000	84.0 (65.7 - 110.1)	69.2 (47.3 - 89.9)	0.125
Fat intake (g)	69.8 ± 17.5	52.7 ± 29.8	0.250	87.1 ± 39.5	70.2 ± 53.2	0.250
Carbohydrate intake (g)	203.5 ± 44.4	134.9 ± 66.8	0.500	221.2 ± 93.2	187.0 ± 131.5	0.625
Niacin equivalent (mg/day)	32.5 (30.6 - 36.5)	40.9 (29.1 - 44.1)	1.000	35.8 (31.9 - 41.6)	29.9 (21.7 - 37.7)	0.125
Physical activity (Total Baecke)	8.1 ± 0.7	8.3 ± 1.5	0.500	8.0 ± 1.7	8.0 ± 1.5	1.000
Alcohol intake (doses/week)	1.0 (0.5 - 1.4)	0.0 (0.0 - 7.0)	1.000	2.0 (0.0 - 4.6)	0.0 (0.0 - 2.5)	1.000
Current smoker (number)	2	1	-	1	1	-
HbA1c (mmol/mol)	34.5 (33.0 - 36.3)	35.5 (34.5 - 36.3)	1.000	36.5 (35.0 - 37.8)	37.0 (35.5 - 38.5)	0.371
Fasting glucose (mmol/l)	5.4 (5.0 - 5.8)	5.4 (5.2 - 5.6)	0.850	5.8 (5.6 - 5.4)	5.4 (5.2 - 5.5)	0.625
Fasting insulin (mIU/l)	7.7 (3.9 - 11.5)	6.1 (.3 - 11.9)	0.875	9.7 (4.1 - 14.9)	10.4 (4.4 - 16.2)	0.125
Fasting C-peptide (nmol/l)	0.7 (0.4 - 1.0)	0.6 (0.4 - 1.0)	0.875	0.8 (0.4 - 1.2)	0.8 (0.4 - 1.1)	0.250
HOMA index	1.8 (1.0 - 2.7)	1.5 (0.8 - 2.8)	0.875	2.5 (1.0 - 3.8)	2.4 (1.0 - 4.0)	1.000
Matsuda index	8.8 ± 6.9	6.9 ± 5.0	0.250	7.5 ± 6.5	5.3 ± 4.5	0.125
Glucose AUC during OGTT	14.8 ± 4.1	15.4 ± 3.2	0.875	16.8 ± 3.3	24.4 ± 13.1	0.625
Insulin AUC during OGTT	90 (30 - 161)	107 (49 - 190)	0.125	115 (39 - 188)	108 (45 - 200)	0.625
Adiponectin (µg/ml)	3.4 (2.8 - 6.8)	3.2 (2.4 - 6.9)	0.750	5.2 (3.6 - 6.9)	5.0 (3.7 - 6.2)	1.000
Cholesterol (total, mmol/l)	4.7 ± 0.5	4.9 ± 0.5	0.181	4.8 ± 0.8	4.7 ± 0.5	0.371
HDL (mmol/l)	1.3 (1.2 - 1.4)	1.4 (1.3 - 1.4)	0.875	1.4 (1.2 - 1.6)	1.3 (1.1 - 1.4)	0.098

LDL (mmol/l)	3.1 ± 0.41	3.4 ± 0.57	0.174	3.3 ± 0.45	3.4 ± 0.47	0.174
Triglycerides (mmol/l)	1.0 (0.9 - 1.0)	1.0 (0.8 - 1.3)	0.875	0.9 (0.7 - 1.2)	0.9 (0.8 - 1.1)	1.000
FFA (µmol/l)	427.7 (325.4 - 531.4)	415.3 (347.7 - 485.2)	0.625	394.1 (332.1 - 481.9)	456.3 (346.6 - 551.1)	0.625
Systolic BP (mmHg)	114 ± 12	122 ± 11	0.250	126 ± 8	129 ± 16	0.625
Diastolic BP (mmHg)	74 ± 9	80 ± 12	0.125	80 ± 5	82 ± 13	0.713
Pulse (per min)	63 ± 8	63 ± 13	1.000	61 ± 5	61 ± 13	0.875
Hs-CRP (mg/l)	1.6 (1.3 - 11)	2.0 (0.9 - 5.5)	0.250	1.0 (0.6 - 3.3)	0.4 (0.4 - 5.1)	1.000
Total homocysteine (µmol/l)	13.0 (12.2 - 13.8)	14.0 (12.1 - 15.8)	0.414	12.5 (11.5 - 15.0)	13.5 (12.1 - 17.0)	0.198
ALT (U/l)	24 (18 - 39)	24 (21 - 33)	1.000	23 (22 - 28)	27 (21 - 34)	1.000
AST (U/l)	27 (25 - 30)	23 (22 - 26)	0.250	27 (24 - 30)	31 (26 - 34)	0.581
Creatinine (µmol/l)	74 ± 13	75 ± 8	0.875	79 ± 12	76 ± 5	0.625
Haemoglobin (g/l)	137 ± 10	132 ± 6	0.197	136 ± 13	130 ± 12	0.197
Haematocrit (%)	40.8 ± 2.9	39.5 ± 2.1	0.173	40.5 ± 3.9	38.5 ± 3.0	0.174
Erythrocytes (x10 ¹² /l)	4.5 ± 0.4	4.5 ± 0.3	0.875	4.6 ± 0.5	4.5 ± 0.4	0.250
MCV (fl)	90.3 ± 2.1	88.3 ± 3.9	0.250	87.8 ± 4.2	86.3 ± 5.6	0.346
MCH (pg)	30.5 ± 1.0	29.8 ± 0.96	0.149	29.8 ± 1.7	29.0 ± 2.2	0.371
MCHC (g/l)	338.0 (335.5 - 339.8)	335.0 (332.5 - 338.0)	1.000	338.5 (334.5 - 342.5)	335.5 (331.3 - 339.3)	0.625
Leukocytes (x10 ⁹ /l)	7.3 ± 3.0	7.0 ± 2.4	0.875	6.2 ± 1.7	6.0 ± 0.9	1.000
Thrombocytes (x10 ⁹ /l)	234 ± 29	260 ± 48	0.197	260 ± 53	238 ± 31	0.375
fP-Fe (µmol/l)	20.0 ± 6.4	20.4 ± 3.2	1.000	20.0 ± 9.1	16.6 ± 5.1	0.875

Data are shown as mean ± standard deviation or median (interquartile range). P values were obtained using paired Wilcoxon rank-sum test to examine the effect of placebo and NR treatments on anthropometric and clinical parameters in the twins from the BMI-concordant pairs (n= 4 pairs/8 individuals). HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment; AUC, area under curve; OGTT, oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acids; BP, blood pressure; Hs-CRP, high sensitive C-reactive protein; ALT, alanine aminotransferase; AST, aspartate transaminase; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; fP, fasting plasma and Fe, iron.

Table S11. The effect of NR on safety parameters in the twins from BMI-discordant pairs.

Variable (unit)	All		P Value	Leaner		P Value	Heavier		P Value
	Pre (<i>n</i> =32 individuals)	Post (<i>n</i> =32 individuals)		Pre (<i>n</i> =16 individuals)	Post (<i>n</i> =16 individuals)		Pre (<i>n</i> =16 individuals)	Post (<i>n</i> =16 individuals)	
ALT (U/l)	22 (18 - 43)	26 (17 - 43)	0.674	20 (17 - 34)	26 (19 - 36)	0.041	33 (20 - 49)	27 (17 - 44)	0.155
AST (U/l)	24 (22 - 31)	25 (21 - 30)	0.626	24 (20 - 29)	24 (21 - 35)	0.081	24 (23 - 31)	25 (22 - 28)	0.293
Creatinine ($\mu\text{mol/l}$)	74 \pm 13	74 \pm 12	0.650	73 \pm 14	75 \pm 12	0.551	74 \pm 13	74 \pm 12	0.924
Haemoglobin (g/l)	142 \pm 9	140 \pm 9	0.043	142 \pm 8	140 \pm 8	0.312	143 \pm 9	141 \pm 10	0.073
Haematocrit (%)	42.0 \pm 2.2	42.1 \pm 2.2	0.641	41.9 \pm 2.1	42.4 \pm 1.9	0.212	42.1 \pm 2.4	41.9 \pm 2.6	0.668
Erythrocytes ($\times 10^{12}/\text{l}$)	4.8 \pm 0.3	4.8 \pm 0.3	0.991	4.8 \pm 0.37	4.8 \pm 0.32	0.244	4.8 \pm 0.31	4.8 \pm 0.31	0.268
MCV (fl)	87.9 \pm 3.5	88.0 \pm 3.3	0.829	88.4 \pm 4.2	88.3 \pm 3.7	1.000	87.4 \pm 2.6	87.7 \pm 2.9	0.681
MCH (pg)	29.8 \pm 1.3	29.4 \pm 1.4	0.013	29.9 \pm 1.5	29.3 \pm 1.7	0.009	29.6 \pm 1.2	29.6 \pm 1.1	0.766
MCHC (g/l)	338 (334 - 342)	333 (330 - 340)	0.005	338 (334 - 342)	332 (327 - 338)	0.010	337 (335 - 342)	336 (331 - 341)	0.300
Leukocytes ($\times 10^9/\text{l}$)	6.4 \pm 1.5	6.3 \pm 1.8	0.134	6.5 \pm 1.8	6.3 \pm 2.0	0.277	6.3 \pm 1.2	6.3 \pm 1.7	0.244
Thrombocytes ($\times 10^9/\text{l}$)	243 \pm 55	248 \pm 62	0.199	244 \pm 60	252 \pm 72	0.301	241 \pm 52	244 \pm 52	0.569
fP-Fe ($\mu\text{mol/l}$)	19.0 \pm 6.9	16.7 \pm 5.9	0.078	19.8 \pm 7.6	16.6 \pm 5.9	0.084	18.1 \pm 6.3	16.7 \pm 6.1	0.349

Data are shown as mean \pm standard deviation or median (interquartile range). P values were obtained using paired Wilcoxon rank-sum test to examine the effect of NR supplementation on safety measures in the twins from the BMI-discordant pairs (*n*=16 twin pairs/32 individuals). ALT, alanine aminotransferase; AST, aspartate transaminase; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; fP, fasting plasma and Fe, iron.